SP1 and familial pancreatic carcinoma: In addition, in tumors dependent on SP1, it provides insight into approaches to develop novel combination therapies that perhaps amplify the targeting of SP1, as has been described with tolfenamic acid in pancreatic cancer (Jia et al, 2010).